Astrocyte Pharmaceuticals Inc.
Astrocyte Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative neuroprotection therapies for traumatic brain injuries (TBI), concussions, stroke, and neurodegenerative disorders. The company focuses on harnessing the potential of astrocytes, the brain's natural caretaker cells, to treat brain injuries and diseases. Their flagship program, AST-004, aims to significantly reduce early brain damage and is advancing to Phase 2 clinical trials.
Astrocyte Pharmaceuticals Inc.
93 Shennecossett Road, Groton, CT 06340
Astrocyte Pharmaceuticals Inc. is currently seeking investment
Astrocyte Pharmaceuticals Inc. is seeking a investment in the range of
Patents
Compounds and methods for treating neurological and cardiovascular conditions
2025-03-04 • US-12239654-B2
View DetailsCompounds and methods for treating addiction and related disorders
2023-12-12 • US-11839615-B2
View DetailsCompounds and methods for treating neurological and cardiovascular conditions
2022-11-01 • US-11484545-B2
View DetailsCompounds and methods for treating neurological and cardiovascular conditions
2021-03-23 • US-10953031-B2
View DetailsWhat We Do
Astrocyte Pharmaceuticals develops therapies for traumatic brain injuries, concussions, stroke, and neurodegenerative disorders by leveraging the potential of astrocytes.
AST-004 is a novel small molecule candidate in clinical trials for treating acute ischemic stroke, TBI, concussion, and neurodegenerative diseases. It has shown promise in reducing brain lesion growth and damage.
Application Area
Drugs
Key People
Co-Founder and Chief Executive Officer
Co-Founder and Advisor
Vice-President of Research
Chief Medical Advisor
Vice-President of Clinical Development Operations
Funded Projects
Astrocyte Announces Initiation of First-In-Human Phase 1 Study of the Promising Stroke and Traumatic Brain Injury Therapeutic, AST-004
Astrocyte Pharmaceuticals has begun a Phase 1 trial for AST-004, a potential treatment for stroke, TBI, and neurodegenerative diseases. The study, funded partly by MTEC and the U.S. Army, will assess safety in 52 healthy participants. If successful, it will progress to Phase 2 trials.
News & Updates
Astrocyte Pharmaceuticals was named 'Innovator of the Month' by Senator Chris Murphy for their work in advancing cerebroprotective therapies.
Astrocyte Pharmaceuticals received FDA clearance for its Investigational New Drug Application for AST-004, paving the way for Phase 2 trials.
The Alzheimer’s Drug Discovery Foundation joined Astrocyte Pharmaceuticals’ $6M+ pre-Series B financing round to expand the development of AST-004.
Theodore Liston, Ph.D., Vice President of Research at Astrocyte, received the 2022 Innovation and Progress Award from the journal Stroke for his work on AST-004.